20. CHANGES IN PLASMA MATRIX METALLOPROTEINASE-9 CONCENTRATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN AND OUT OF EXACERBATION AT MILITARY HOSPITAL 103 IN 2023
Main Article Content
Abstract
Objective: To describe changes in plasma Matrix Metalloproteinase-9 concentrations in patients with chronic obstructive pulmonary disease in and out of exacerbation at 103 Military Hospital in 2023.
Subjects and methods: A case-control study on 35 COPD patients treated inpatients at the Respiratory Center, Military Hospital 103 and 30 healthy people. Quantification of plasma MMP-9 levels by using ELISA technique.
Results: There was no difference between plasma MMP-9 concentrations in COPD patients in and out of exacerbations, compared to healthy groups (p > 0.05). Plasma MMP-9 concentrations during exacerbation increased significantly in the group of patients with increased white blood cell counts (p < 0.001). Patients treated by corticosteroids before admission had lower plasma MMP-9 concentrations than the group without corticosteroids treatment (p < 0.001). Plasma MMP-9 concentrations in COPD patients after the exacerbation increased significantly in current smokers, comparing with current non-smokers (p < 0.001). After the exacerbation, patients with COPD type PP had a median plasma MMP-9 concentration of 61.2 ng/mL, significantly higher than patients with COPD type BB (p = 0.009).
Conclusions: In the exacerbation, plasma MMP-9 concentrations were higher in patients with increased white blood cell counts and lower in patients using corticosteroids. After the exacebation, plasma MMP-9 concentrations were higher than in patients who had COPD type PP and were current smokers.
Article Details
Keywords
Chronic obstructive pulmonary disease (COPD); serum MMP-9.
References
in lung health and disease": Matrix metalloproteinases in
COPD, Eur Respir J, 39(1), 2012, pp. 197-209.
[2] Dimic-Janjic S, Hoda MA et al., The usefulness
of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio
for diagnosis and assessment of COPD severity,
Eur J Med Res, 28(1), 2023, pp. 127.
[3] Kang MJ, Oh YM et al., Lung matrix metalloproteinase-
9 correlates with cigarette smoking and obstruction
of airflow, J Korean Med Sci, 18(6), 2003, pp. 821-7.
[4] Li Y, Lu Y et al., Relationships of MMP-9 and
TIMP-1 proteins with chronic obstructive pulmonary
disease risk: A systematic review and
meta-analysis, J Res Med Sci, 21, 2016, pp. 12.
[5] Linder R, Rönmark E et al., Serum metalloproteinase-9
is related to COPD severity and symptoms - cross-
sectional data from a population based cohort-study,
Respir Res, 16(1), 2015, pp.28.
[6] The Global Initiative for Chronic Obstructive
Lung Disease, Global stragery for prevention,
diagnosis and management of COPD: 2023 Report, 2023.
[7] Mahor D, Kumari V et al., Elevated serum matrix
metalloprotease (MMP-2) as a candidate
biomarker for stable COPD, BMC Pulm Med,
20(1), 2020, pp. 302.
[8] Russell RE, Culpitt SV et al., Release and activity
of matrix metalloproteinase-9 and tissue inhibitor of
metalloproteinase-1 by alveolar macrophages from
patients with chronic obstructive pulmonary disease,
Am J Respir Cell Mol Biol, 26(5), 2002, pp. 602-9.